Abstract:Shao-Li Huang, 1– 3, &ast Hong-Yi Xin, 4, 5, &ast Xiao-Yan Wang, 4, 5, &ast Guang-Gui Feng, 3 Fu-Qing Wu, 3 Zhi-Peng Feng, 6 Zhou Xing, 2 Xi-He Zhang, 4, 5 Hong-Wu Xin, 4, 7, 8 Wen-Ying Luo 1 1 Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524400, People's Republic of China; 2 First Clinical College, Guangdong Medical University, Guangdong, 524400, People's Republic of China; 3 Clinical laboratory, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 4 Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 5 Guangdong Medical University Affiliated Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China; 6 Department of Gastroenterology, Yueyang Hospital Affiliated to Hunan Normal University, Yueyang, Hunan, 414000, People's Republic of China; 7 Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei, 434023, People's Republic of China; 8 Research Centre of Molecular Medicine, Medical College of Chifeng University, Chifeng, Inner Mongolian Autonomous Region, 024000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen-Ying Luo, Medical laboratory Center, Affiliated Hospital of Guangdong Medical University, 57th South Renmin Road, Zhanjiang, 524001, People's Republic of China, Tel +86 18312728748, Email Xi-He Zhang, Doctoral Scientific Research Center, Lianjiang People's Hospital, Guangdong, 524400, People's Republic of China, Tel +86 19126491230, Email Venous thromboembolism is a condition that includes deep vein thrombosis and pulmonary embolism. It is the third most common cardiovascular disease behind acute coronary heart disease and stroke. Over the past few years, growing research suggests that venous thrombosis is also related to the immune system and inflammatory factors have been confirmed to be involved in venous thrombosis. The role of inflammation and inflammation-related biomarkers in cerebrovascular thrombotic disease is the subject of ongoing debate. P-selectin leads to platelet-monocyte aggregation and stimulates vascular inflammation and thrombosis. The dysregulation of miRNAs has also been reported in venous thrombosis, suggesting the involvement of miRNAs in the progression of venous thrombosis. Plasminogen activator inhibitor-1 (PAI-1) is a crucial component of the plasminogen-plasmin system, and elevated levels of PAI-1 in conjunction with advanced age are significant risk factors for thrombosis. In addition, it has been showed that one of the ways that neutrophils promote venous thrombosis is the formation of neutrophil extracellular traps (NETs). In recent years, the role of extracellular vesicles (EVs) in the occurrence and development of VTE has been continuously revealed. With the advancement of research technology, the complex regulatory role of EVs on the coagulation process has been gradually discovered. However, our understanding of the causes and consequences of these changes in venous thrombosis is still limited. Therefore, we review our current understanding the molecular mechanisms of venous thrombosis and the related clinical trials, which is crucial for the future treatment of venous thrombosis. Keywords: venous thromboembolism, miRNA, neutrophil extracellular traps, plasminogen activator inhibitor-1, EVs, inflammatory factor Venous thromboembolism (VTE) is a multifaceted, potentially fatal event that activates coagulation and fibrinolysis. 1 It is a condition that includes pulmonary embolism (PE) and deep vein thrombosis (DVT). 2 In addition, it is also the third most prevalent cardiovascular disease after stroke and coronary heart disease (CHD). 3 Venous thrombosis (VT) is a leading cause of mortality as well as morbidity worldwide, occurring in approximately one case in 1000 people per year in affluent nations. 4 DVT is the thrombosis that blocks the deep venous cavity, disrupting the venous reflux network and resulting in chronic deep venous dysfunction. 5,6 Furthermore, DVT is a consequence of a complicated interaction between enzymes and cellular processes, in which the endothelium, platelets, and leukocytes coordinate a pro-inflammatory state that ultimately leads to the clot formation 7 with higher mortality rate for acute DVT. 8 To date, vascular ultrasound and digital subtraction angiography are the primary techniques for diagno -Abstract Truncated-

Synergic Effect Of Gpiba And Von Willebrand Factor In Pathogenesis Of Deep Vein Thrombosis

Experimental Study of Interaction Between Activated VWF and Targeted Lipid Microbubbles Conjugated with Recombinant GPIba

Experimental study of interaction between activated VWF and targeted lipid microbubbles conjugated with recombinant GPⅠba

Deep Vein Thrombosis Is Facilitated by Endothelial-Derived Extracellular Vesicles via the PDI–GRP94–GPIIb/IIIa Pathway in Mice

Thrombosis and Inflammation-A Dynamic Interplay and the Role of Glycosaminoglycans and Activated Protein C

Novel GPIb-independent platelet aggregation induced by botrocetin: Implications for diagnosis and antithrombotic therapy

Role of Platelets and Their Interaction with Immune Cells in Venous Thromboembolism

Platelet-Derived TGF-β1 Promotes Deep Vein Thrombosis

Dual roles of fucoidan-GPIbα interaction in thrombosis and hemostasis: implications for drug development targeting GPIbα

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Blood Cell Parameters Combined with Inflammatory Markers in the Early Diagnosis of Pulmonary Embolism

Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure

Essential role of glycoprotein Ibα in platelet activation

Procoagulant platelet activation promotes venous thrombosis

Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation

Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism

Abstract 3094: Traditional Chinese Medicine Buyang Huanwu Decoction Regulates The Platelet Gpvi And Its Downstream Protein Signaling Pathways,inhibiting Thrombosis And Preventing Cardiovascular Disease.

PATHOPHYSIOLOGICAL MECHANISMS OF DEEP VEIN THROMBOSIS

GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease

Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects